CEOs earned 32- to 215- times that of the median worker at six device companies. Find out which CEO earned $10.8 billion–215 times the median salary–and see how company revenues compare to the CEO/worker pay ratio. The average ratio for the six firms is 150-1: Discover how this compares to other public companies across industries.
Biopharma industry veteran Tadataka “Tachi” Yamada sits down with In Vivo for an exclusive interview that draws on his years of experience in many roles across the R&D ecosystem to explore the state of today’s biopharma R&D enterprise.
Access this exclusive In Vivo interview with Tom McGuinness, President and CEO, Imaging at GE Healthcare. He reveals GE’s secret to success in speed-to-market product launches, and explains how GE is using data analytics and software innovations to reach patients, faster.
Insurers and a neurologist testifying at a May 16 Senate Finance Committee hearing on the CHRONIC Care Act praised the bill’s telehealth provisions. Committee Chairman Orrin Hatch, R-Utah, says he plans to mark up the bill, which has been under development for two years, this week.
OTC drug firms should offer more digital tools that guide consumers in product purchases, says a health care marketing executive. The American Pharmacists Association suggests firms also strengthen outreach with pharmacists.
RB’s spending on the WebMD-hosted Cold & Flu Tracker app generated an ROI three times greater than traditional digital marketing, says marketing executive Emma Howe. Similar campaigns are gaining momentum, with WebMD and Walgreens launching “Relief Advisor.”
Connected care technologies play an important role in disease prevention, but are still not used as widely as they should be. Philips’ second Future Health Index study surveyed 33,000 participants in 19 countries to compare perceptions and experiences of healthcare users across three areas – access to care, integration of health systems and adoption of connected care technologies.
A digital video game developed by Akili Interactive Labs for treating cognitive disorders has demonstrated in a pilot study its ability to improve cognitive control test scores of neurotypical children and children with sensory processing dysfunction (SPD).
Victoria Hordern and Amy Merrick discuss initiatives in the EU to help app developers navigate the unclear rules on mobile health and explain why engaging patients during product development is key.
Biogen’s chief medical officer says iPhone technology should in future be used for early warning diagnosis of Alzheimer’s Disease. Biogen CMO Alfred Sandrock has told a London neuroscience forum that constraints impeding CNS drug development include the fact diagnosis needs to be done earlier but that barrier could be mitigated in future by digital health solutions such iPhones used as “early warning” diagnostics, notably in Alzheimer’s Disease.
The digitalization of health care has been much talked about over the last decade or so. But activity among the medical device manufacturers and service providers has only just recently accelerated as they start overcoming barriers and resistance to this new way of delivering health care.
Should big pharma still do in-house discovery and early development? Maybe not; GSK’s unsuccessful efforts to boost productivity suggest it’s impossible for big pharma to re-create biotech-like innovation internally. Learn why big pharma should stick to late-stage development and how it can maintain its competitive advantage.
> Reckitt Reaps ROI Reward In Geo-Targeted Symptoms App Promoting Mucinex, Delsym > Biogen CMO Notes iPhone’s Potential For Early Detection of Alzheimer’s > Interview: Philips Plugs Into Patient Connectivity
> Behind The Scenes Of Digital Health: Medtech Players And Partners > Philips To Create More Context, Connectedness And Continuity And Shift Sick Care To Health Care > New Data Gives Adherium Fuel To Accelerate Digital Tech Adoption in Drug Sector > Siemens Healthineers To Launch Digital ‘One-Stop-Shop’
> Engaging Patients and Navigating Laws: What To Consider When Developing Health Apps > Telehealth Reforms Praised At Senate Hearing > Philips’ Survey Highlights Gaps In Perceptions Of Health Care > Game On For Akili’s Cognitive Control Tech
Funding is taking a long time to come through for the UK NHS’s digital health care transformation, but as the national provider’s head of technology strategy, Dr Paul Rice says, “We can’t afford to remain non-digital.”
Preventing cyberattacks on medical technology occupies the waking thoughts of device software manufacturers, but the global ransomware episode in mid-May shows that companies must also be alive to threat posed to their provider customers.
Ongoing pressures on drug pricing and reimbursement mean that current research and development (R&D) economics are unsustainable. The process of discovering and developing a drug has not fundamentally changed for decades, and on average it still costs $2.6bn and takes over 10 years. Fortunately, tools are emerging to help improve R&D success rates. Most are built on better use of more kinds of data, including using artificial intelligence (AI) to process massive quantities of information that humans cannot manage. Some of these new tools promise cost and time savings of between 20–50%
The digital medtech sector is growing fast. As new companies enter the space, they are going to face oversight from a slew of government agencies and statutes.
This 17-country study finds that continued growth of mobile technologies and e-commerce,combined with a more stable regulatory environment, are driving changes in the European mail order and Internet pharmacy market.
Data plays a key role in healthcare systems’ shifts towards value-focused outcomes. Such data includes outcomes and cost data, adherence data, and increasingly, patient-reported data, behavioral and social media data.
Real-world evidence promises to solve many problems inherent in getting a drug to patients at a good price. It could slash development costs and help make the reimbursement case to payers. But there are challenges for companies that want to exploit real-world evidence to get their drug to patients in Europe.
Wearable technologies have the potential to transform medicine and the delivery of healthcare more significantly than any other component of the digital revolution – or indeed than many other scientific advances.
The Intersection Between Tech and Pharma Special Report (Part 3. Intel, Samsung, IBM, and GE)
This comprehensive study identifies key factors driving change in the channels through which non-prescription/OTC medicines are distributed in Europe (18 main EU markets, plus Norway and Switzerland) and highlights the challenges facing suppliers in an ever-changing market.
In January 2015, Fortune reported that at $2.9tn, the state of the US healthcare industry is very strong and continues to grow. Additionally, a Top Issues report revealed that 40% of Fortune 50 companies pursued new healthcare partnerships in 2014. Given the rapid change in the healthcare industry over the last few years, it is no surprise that we are starting to see more non-traditional healthcare partnerships, specifically with big tech companies.
In January 2015, Fortune reported that at $2.9tn, the state of the US healthcare industry is very strong and continues to grow.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!